SCHEMBL6441607

SCHEMBL6441607

CC(N)C(O)c1ccc([N+](=O)[O-])cc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.53
KDM4E B2RXH2 4/20 0.53
LMNA P02545 3/20 0.52
HIF1A Q16665 2/20 0.52
ADRA2A P08913 1/20 0.52
ADRA2C P18825 1/20 0.52
MAPT P10636 3/20 0.50
KMT2A Q03164 2/20 0.50
MEN1 O00255 1/20 0.50
NPC1 O15118 1/20 0.47
CA12 O43570 1/20 0.47
CA1 P00915 1/20 0.47
CA2 P00918 1/20 0.47
CA9 Q16790 1/20 0.47
CA14 Q9ULX7 1/20 0.47
TSHR P16473 3/20 0.47
CYP3A4 P08684 2/20 0.47
SMN1; SMN2 Q16637 1/20 0.47
MARS2 Q96GW9 1/20 0.47
CYP2C19 P33261 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18383388 1.00 ALDH1A1 (0.53) ALDH1A1KDM4ELMNAHIF1AADRA2A
SCHEMBL6824923 1.00 ALDH1A1 (0.53) ALDH1A1KDM4ELMNAHIF1AADRA2A
Hydrochloric Acid SCHEMBL31568880 0.98 ALDH1A1 (0.53) ALDH1A1KDM4ELMNAHIF1AADRA2A
SCHEMBL11614118 0.86 ALDH1A1 (0.50) ALDH1A1KDM4ELMNAMAPTKMT2A
SCHEMBL12159675 0.85 ALDH1A1 (0.56) ALDH1A1KDM4ELMNAMAPTKMT2A
SCHEMBL18517040 0.85 ALDH1A1 (0.55) ALDH1A1KDM4ELMNAMAPTKMT2A
SCHEMBL18116758 0.81 ALDH1A1 (0.53) ALDH1A1KDM4ELMNAMAPTKMT2A
SCHEMBL18211541 0.81 MEN1 (0.54) ALDH1A1KDM4ELMNAMAPTKMT2A
SCHEMBL22577634 0.81 ALDH1A1 (0.51) ALDH1A1KDM4ELMNAMAPTKMT2A
SCHEMBL811522 0.80 ALDH1A1 (0.52) ALDH1A1KDM4EMAPTKMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10000555-B2 Monomethylvaline compounds having phenylalanine side-chain modification at the C-terminus SEATTLE GENETICS, INC. (US) 2018-06-19 US disclosed
US-20170014524-A1 AURISTATIN-ANTIBODY CONJUGATES AND USES THEREOF THE SCRIPPS RESEARCH INSTITUTE 2017-01-19 US disclosed
US-20130123465-A1 MONOMETHYLVALINE COMPOUNDS HAVING PHENYLALANINE SIDE-CHAIN MODIFICATIONS AT THE C-TERMINUS SEATTLE GENETICS, INC. (US) 2013-05-16 US disclosed
US-8343928-B2 Monomethylvaline compounds having phenylalanine side-chain replacements at the C-terminus SEATTLE GENETICS, INC. (US) 2013-01-01 US disclosed
US-6894190-B2 Process for producing optically active 3,3,3-trifluoro-2-hydroxy-2-methylpropionic acid, and salt thereof SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2005-05-17 US disclosed
US-20030232886-A1 Process for producing optically active 3,3,3-trifluoro-2-hydroxy-2-methylpropionic acid, and salt thereof SUMITOMO CHEMICAL COMPANY, LIMITED 2003-12-18 US disclosed
US-6653507-B2 Useful intermediate compound of pharmaceuticals for urinary incontinence SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2003-11-25 US disclosed
US-20020143212-A1 Process for producing optically active 3,3,3-trifluoro-2-hydroxy-2-methylpropionic acid, and salt thereof SUMITOMO CHEMICAL COMPANY, LIMITED 2002-10-03 US disclosed
US-6403832-B1 MIXING ACID WITH AMINE, PRECIPITATING SALT, AND FILTERING; GOOD OPTICAL PURITY SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2002-06-11 US disclosed
EP-1074539-A2 Process for producing optically active 3,3,3,-trifluoro-2-hydroxy-2-methylpropionic acid, and salt thereof SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2001-02-07 EP disclosed
EP-0055689-B1 3-SUBSTITUTED 2,4,6-TRIHALOGENOBENZAMIDES AND THEIR SALTS, THEIR PREPARATION AND THEIR USE AS SUBSTITUTES FOR NATURAL SWEETENING AGENTS, AND SWEETENERS CONTAINING THEM SCHERING AKTIENGESELLSCHAFT (DE) 1984-07-04 EP disclosed
EP-0055689-A1 3-Substituted 2,4,6-trihalogenobenzamides and their salts, their preparation and their use as substitutes for natural sweetening agents, and sweeteners containing them SCHERING AKTIENGESELLSCHAFT (DE) 1982-07-07 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130123465-A1 MONOMETHYLVALINE COMPOUNDS HAVING PHENYLALANINE SIDE-CHAIN MODIFICATIONS AT THE C-TERMINUS MMAB, PTMS, DNPEP ALDH1A1 3562/4885KDM4E 648/4885LMNA 578/4885
US-20030232886-A1 Process for producing optically active 3,3,3-trifluoro-2-hydroxy-2-methylpropionic acid, and salt thereof ALDH1A2, CYP8B1, CYP11B2 ALDH1A1 141/4885KDM4E 3102/4885LMNA 1166/4885
US-20020143212-A1 Process for producing optically active 3,3,3-trifluoro-2-hydroxy-2-methylpropionic acid, and salt thereof ALDH1A2, ALDH7A1, ALDH18A1 ALDH1A1 73/4885KDM4E 2234/4885LMNA 1926/4885
US-20170014524-A1 AURISTATIN-ANTIBODY CONJUGATES AND USES THEREOF AURKC, AURKA, AURKB ALDH1A1 1213/4885KDM4E 2352/4885LMNA 3359/4885
US-10000555-B2 Monomethylvaline compounds having phenylalanine side-chain modification at the C-terminus PTMS, MMAB, DNPEP ALDH1A1 3502/4885KDM4E 608/4885LMNA 572/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.